E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced/metastatic ovarian cancer resistant or refractory to platinum. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033128 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the antitumor activity of brostallicin as second/third line chemotherapy in adult patients with advanced/ metastatic ovarian cancer resistant/refractory to platinum based therapy. |
|
E.2.2 | Secondary objectives of the trial |
To determine the safety profile of brostallicin in these patients. To assess the time-related efficacy endpoints. To monitor response to therapy by tumor marker evaluation. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.Histologically or cytologically proven diagnosis of advanced/metastatic epithelian ovarian cancer 2.Progressive disease after at least one prior platinum based regimen 3.Age / 18 4.Eastern Cooperative Oncology Group ECOG performance status PS of 0 or 1 5.Life expectancy of / 3 months at study entry i.e. from informed consent signature date 6.At least one measurable lesion according to RECIST criteria 7.All acute toxic effects excluding alopecia of any prior therapy must have resolved to CTCAE Version 3.0 Grade / 1 8.Required initial laboratory data to be eligible for study entry are Absolute neutrophil count ANC / 1,500/mm3 / Grade 1 , Platelets PLT / 100,000/mm3, Hemoglobin / 10.0 g/dL / Grade 1 , Total serum bilirubin / 1.5 x ULN / Grade 1 , Liver transaminases AST/ALT / 2.5 x ULN; / Grade 1 ; in case of liver metastasis / 5 x ULN , Alkaline Phosphatase ALP / 2.5 x ULN / Grade 1 ; in case of liver metastasis / 5 x ULN , Serum Albumin / 3.0 g/dL / Grade 1 , Serum creatinine / 1.25 x ULN / 133 mcmol/L and/or creatinine clearance / 60 mL/min 9.Wash out period of at least 4 weeks from surgery, from radiotherapy or from previous chemotherapy 10.Negative serum pregnancy test for females of childbearing potential / 7 days before starting treatment 11.Signed written informed consent prior to beginning protocol specific procedures 12.Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. |
|
E.4 | Principal exclusion criteria |
1.Patients who received more than 2 prior chemotherapy lines of treatment for advanced/metastatic ovarian cancer 2.Second malignancies. Patients with prior history of other malignancies must have been disease free for / 5 years. Previous histories of basal cell carcinoma of the skin or in situ carcinoma of the cervix are accepted 3.Patients with clinically significant cardiac disease or myocardial infarction within the last 6 months before study entry 4.Known brain or leptomeningeal disease CT-scan or MRI of the brain required only in case of clinical suspicion of central nervous system metastases 5.Active uncontrolled infection including known positive human immunodeficiency virus HIV 6.Pregnancy or breast-feeding. Patients must agree to avoid becoming pregnant during the study and in the following 3 months after the end of the treatment, be surgically sterile or be postmenopausal. 7.Irradiation to / 25 of her bone marrow 8.Concomitant treatment with any other anti-cancer therapy and/or investigational agent 9.Patients who have participated in any investigational drug study within 4 weeks preceding treatment start 10.Medical or psychological condition that would not permit the patient to complete the trial or understand and sign informed consent. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Objective tumor response rate RR the RECIST criteria will be used to assess responses. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |